Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 83

Results For "24"

2058 News Found

OneSource receives EIR with VAI classification from USFDA for BLD facility
Drug Approval | January 29, 2025

OneSource receives EIR with VAI classification from USFDA for BLD facility

OneSource operates five cGMP facilities and has a strong track record, with 138 successful regulatory and customer audits to date by all major regulatory bodies


Torrent Pharmaceuticals posts Q3 FY25 consolidated PAT at Rs. 503 Cr
News | January 28, 2025

Torrent Pharmaceuticals posts Q3 FY25 consolidated PAT at Rs. 503 Cr

Torrent Pharmaceuticals has reported total income of Rs. 2,842 crores during the period ended December 31, 2024


RPG Life Sciences posts Q3 FY25 PAT higher at Rs. 34.93 Cr
News | January 28, 2025

RPG Life Sciences posts Q3 FY25 PAT higher at Rs. 34.93 Cr

RPG Life Sciences has reported total income of Rs. 176.02 crore during the period ended December 31, 2024


Laurus Labs posts Q3 FY25 consolidated PAT higher at Rs. 92.30 Cr
News | January 28, 2025

Laurus Labs posts Q3 FY25 consolidated PAT higher at Rs. 92.30 Cr

Laurus Labs has reported total income of Rs. 1,424.47 crores during the period ended December 31, 2024


Supriya Lifescience posts Q3 FY25 PAT up at Rs. 46.78 Cr
News | January 28, 2025

Supriya Lifescience posts Q3 FY25 PAT up at Rs. 46.78 Cr

The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments


Granules India Q3 FY25 PAT drops 6% to Rs 118 Cr
News | January 27, 2025

Granules India Q3 FY25 PAT drops 6% to Rs 118 Cr

The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations


AstraZeneca plans US$ 570 million investment in Canada
News | January 27, 2025

AstraZeneca plans US$ 570 million investment in Canada

700 new scientific and high-skilled jobs to be created in Greater Toronto Area, investing to execute more than 210 AstraZeneca global clinical studies


Mankind Pharma Q3 FY25 PAT dips 16% to Rs. 385 Cr
News | January 25, 2025

Mankind Pharma Q3 FY25 PAT dips 16% to Rs. 385 Cr

Q3 FY25 revenue up 24% to Rs 3,230 crore


Senores Pharmaceuticals reports revenue of Rs. 288 crore in 9M FY25
News | January 24, 2025

Senores Pharmaceuticals reports revenue of Rs. 288 crore in 9M FY25

PAT after MI is Rs. 41 crore which is 162% increase


Alivus Life Sciences delivers 12% revenue growth
News | January 24, 2025

Alivus Life Sciences delivers 12% revenue growth

EBITDA margins expand to 31.3%